Clinical Trials Logo

Healthy Participants clinical trials

View clinical trials related to Healthy Participants.

Filter by:

NCT ID: NCT06349473 Recruiting - Clinical trials for Healthy Participants

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with severe Hemophilia A or Hemophilia B, with or without inhibitors (Part B).

NCT ID: NCT06348303 Recruiting - Clinical trials for Healthy Participants

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

Start date: March 15, 2024
Phase: Phase 4
Study type: Interventional

Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.

NCT ID: NCT06344728 Recruiting - Clinical trials for Healthy Participants

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

INS1007
Start date: April 30, 2024
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the relative bioavailability of brensocatib between the pediatric oral solution and oral tablets in healthy participants.

NCT ID: NCT06342713 Not yet recruiting - Healthy Volunteers Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035

Start date: May 28, 2024
Phase: Phase 1
Study type: Interventional

This study is the first-in-human (FIH) study for BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035 with both a single dose and multiple doses administered at different dose levels in healthy participants. Study details include: - The study duration will be up to 16 months. - The treatment duration will be up to 14 days. - Safety follow-up 30 days after last dose of study drug.

NCT ID: NCT06337110 Not yet recruiting - Clinical trials for Healthy Participants

A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men

Start date: April 5, 2024
Phase: Phase 1
Study type: Interventional

The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of the body after a single dose is given to healthy male participants.

NCT ID: NCT06315335 Not yet recruiting - Clinical trials for Healthy Participants

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is investigate the safety, tolerability and pharmacokinetic of UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy Caucasian and Japanese participants.

NCT ID: NCT06310824 Not yet recruiting - Clinical trials for Healthy Participants

Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

Start date: May 2024
Phase: Phase 1
Study type: Interventional

A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

NCT ID: NCT06310304 Active, not recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Start date: March 26, 2024
Phase: Phase 1
Study type: Interventional

This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants.

NCT ID: NCT06309394 Recruiting - Clinical trials for Healthy Participants

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

Start date: May 15, 2024
Phase: Phase 1
Study type: Interventional

This study is being conducted to assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants.

NCT ID: NCT06304961 Recruiting - Clinical trials for Healthy Participants

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

Start date: April 8, 2024
Phase: Phase 1
Study type: Interventional

The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms.